Core Viewpoint - Jingtai Holdings (02228) experienced a significant stock increase of over 6%, currently trading at 11.4 HKD, following the announcement of a strategic collaboration with Eli Lilly worth up to 345 million USD [1] Group 1: Strategic Collaboration - Jingtai Technology's subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total value potentially reaching 345 million USD, including several million USD in upfront payments and milestone payments [1] - This partnership aims to leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, while also utilizing its AI antibody research platform to enhance internal pipeline research [1] Group 2: Previous Collaborations - This agreement follows a previous collaboration in 2023, where Jingtai Technology and Eli Lilly signed a 250 million USD deal focused on AI small molecule drugs, marking another significant partnership between the two companies [1] Group 3: Ailux's Development - Ailux, established by Jingtai Technology in 2021, has rapidly developed into a major platform for large molecule drug research, achieving significant commercial results in recent years [1] - The platform employs a hybrid research model that combines wet and dry lab approaches, enabling precise AI-driven antibody drug design and engineering, effectively addressing challenges related to high costs and long timelines in drug discovery [1] - Ailux is expected to advance various next-generation antibody drugs designed by AI into later clinical stages, aiming for impactful major commercial collaborations in the future [1]

Core Insights - Crystal Technology's subsidiary Ailux has entered into a multi-target strategic collaboration and platform licensing agreement with Eli Lilly, valued at up to $345 million [2] - This partnership follows a previous $250 million agreement for AI small molecule drug collaboration, highlighting the ongoing relationship between the two companies [2] - The collaboration aims to accelerate the discovery and development of bispecific antibodies using Ailux's proprietary platform, showcasing the international recognition of its AI capabilities in drug development [2][3] Company Overview - Ailux, established by Crystal Technology in 2021, focuses on the development of large molecule drugs and has rapidly progressed in commercial outcomes over the past two years [3] - The platform integrates quantum physics, AI, and high-throughput wet lab capabilities to design high-potential antibody drugs targeting complex disease mechanisms [3] - Ailux has successfully served multiple top international pharmaceutical companies and validated its platform in several research projects [3] Market Potential - Antibodies are a core drug form that outperforms small molecules in terms of annual growth rate, blockbuster drug ratio, and clinical success rates [2] - The global drug market for antibodies is projected to grow from $288.4 billion in 2025 to $628.5 billion by 2035, indicating a continuous increase in market share [2]